Stocktoria
Genenta Science S.p.A. GNTA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-12-15
Chart by TradingView
2/9
Piotroski F — financial health
0.22
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Operating income | -$6.6M | -$9.8M | -$11.7M | -$11.0M | -$5.7M |
| Net income | -$6.5M | -$8.9M | -$11.6M | -$8.5M | -$5.5M |
| Operating cash flow | -$6.9M | -$6.2M | -$11.2M | -$7.4M | -$7.0M |
| Free cash flow | -$6.9M | -$6.2M | -$11.2M | -$7.4M | -$7.0M |
| Total assets | $31.9M | $14.8M | $22.3M | $33.4M | $40.0M |
| Shareholders' equity | $21.8M | $12.5M | $20.4M | $31.1M | $38.9M |
| Ratios | |||||
| Return on assets | -20.5% | -60.1% | -52.1% | -25.4% | -13.8% |
| Return on equity | -29.9% | -71.3% | -57.0% | -27.2% | -14.2% |
| Current ratio | 14.16 | 6.89 | 12.25 | 14.53 | 34.15 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 0.22 (distress)
- Working capital / assets 0.874
- Retained earnings / assets -1.963
- EBIT / assets -0.207
- Equity / liabilities 2.173
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001838716 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.